HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Remaley, A. T. Search for Related Content PubMed Articles by Remaley, A. T. Related Collections Clinical Case Studies

Commentary

National Institutes of Health, Bethesda, MD.

Address correspondence to the author at: National Institutes of Health, Bldg. 10, Rm. 2C-433, 10 Center Dr, MSC 1508, Bethesda, MD, 20892-1508. Fax 301-402-1885; e-mail aremaley@nih.gov.

The first 20% of the full text of this article appears below.

Although apolipoprotein (apo)A-I and apoB are measured by many laboratories as an adjunct to HDL and LDL concentrations, respectively, lipoproteins contain numerous other proteins, some of which have a profound effect on lipoprotein metabolism. ApoE, for example, resides on both antiatherogenic HDL particles and on proatherogenic apoB-containing lipoproteins, thus confounding the usefulness of apoE as a cardiovascular risk marker in unfractionated samples. Nevertheless, apoE has many different roles in lipoprotein metabolism, some of which . . . [Full Text of this Article]